1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Apr 2020
Admin
News Article

Novartis Announces Plan To Initiate Clinical Trial Of Canakinumab For Patients With Covid-19 Pneumonia

Novartis Today Announced Plans To Initiate A Phase Iii Clinical Trial To Study Canakinumab In Patients With Covid-19 Pneumonia. The Can-Covid Trial Will Examine The Efficacy Of Utilizing Canakinumab, An Interleukin (Il)-1Β Blocker, To Treat A Type Of Severe Immune Overreaction Called Cytokine Release Syndrome (Crs) In People With Covid-19 Pneumonia. Crs Could Lead To Life-Threatening Complications In Patients With Covid-19.(1-3)The Study Builds On Early Evidence From Lab Tests Of Covid-19 Patients Who Showed Elevated Il-1Β Levels, Among Other Cytokines.(2,4)Novartis Aims To Rapidly Enroll 450 Patients At Multiple Medical Centers Across France, Germany, Italy, Spain, Uk And The Us And Randomize Them To Receive Either Canakinumab Or Placebo On Top Of Standard Of Care (Soc). The Primary Objective Of The Study Is To Demonstrate The Benefit Of Canakinumab In Combination With Soc In Increasing The Chance Of Survival Without The Need For Invasive Mechanical Ventilation Among Patients With Covid-19 Pneumonia. Top-Line Results Are Anticipated Late Summer 2020.This Trial Initiation Is Part Of The Overall Novartis Approach To Applying Our Best Science To Tackling The Issues Related To Covid-19 And Further Underscores Novartis Commitment To Quickly Deploy R&Amp;D Resources, Medicines, Clinical Expertise And Philanthropic Aid To Combat Covid-19. About NovartisNovartis Is Reimagining Medicine To Improve And Extend People&Rsquo;S Lives. As A Leading Global Medicines Company, We Use Innovative Science And Digital Technologies To Create Transformative Treatments In Areas Of Great Medical Need. In Our Quest To Find New Medicines, We Consistently Rank Among The World&Rsquo;S Top Companies Investing In Research And Development. Novartis Products Reach Nearly 800 Million People Globally And We Are Finding Innovative Ways To Expand Access To Our Latest Treatments. About 109,000 People Of More Than 145 Nationalities Work At Novartis Around The World.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!